BiotechTube

Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease

Conditions

Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease

Trial Timeline

Nov 1, 1996 → Nov 1, 2004

NCT ID
NCT00231738

About Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)

Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM) is a approved stage product being developed by Mochida Pharmaceutical for Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00231738. Target conditions include Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease.

What happened to similar drugs?

20 of 20 similar drugs in Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease were approved

Approved (20) Terminated (4) Active (0)
✅AbciximabEli LillyApproved
✅AbciximabEli LillyApproved
✅abciximabEli LillyApproved
✅Ticagrelor + ClopidogrelAstraZenecaApproved
✅ticagrelor + aspirinAstraZenecaApproved
✅Ticagrelor + PlaceboAstraZenecaApproved
✅Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)AstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00231738ApprovedCompleted

Competing Products

20 competing products in Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease

See all competitors
ProductCompanyStageHype Score
Butylphthalide + Butylphthalide placeboCSPC Pharmaceutical Group LimitedPhase 3
47
AbciximabEli LillyApproved
43
Prasugrel + ClopidogrelDaiichi SankyoPhase 3
40
Regadenoson + gadofoveset trisodiumAstellas PharmaPhase 2
35
Half-dose of the Tc99-m sestamibi (Cardiolite)Astellas PharmaPre-clinical
18
No interventionAstellas PharmaPre-clinical
22
Empagliflozin + PlaceboEli LillyPhase 3
40
Abciximab + Abciximab placeboEli LillyPhase 3
36
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serumEli LillyPhase 3
40
AbciximabEli LillyApproved
43
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximabEli LillyPhase 3
40
fibrinolytic therapy or combination reduced fibrinolytic therapyEli LillyPhase 3
40
abciximabEli LillyApproved
43
tenecteplase + enoxaparin + clopidogrelEli LillyPhase 2/3
38
Thrombolytic therapyEli LillyPre-clinical
22
TicagrelorAstraZenecaPre-clinical
26
TicagrelorAstraZenecaPhase 2
31
Dual-antiplatelet therapy + Dual-antiplatelet therapyAstraZenecaPre-clinical
22
Metoprolol- Toprol XL + Metoprolol- LopressorAstraZenecaPhase 1
29
Ticagrelor orodispersible tablets + Ticagrelor standard tabletsAstraZenecaPhase 3
40